Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000256 | uM | 12000.145 | 0.9464 | 0.8268 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00128 | uM | 12000.145 | 0.9766 | 0.9237 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0064 | uM | 12000.145 | 0.9534 | 0.8491 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.032 | uM | 12000.145 | 0.9676 | 0.8945 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 12000.145 | 1.0180 | 1.0595 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 12000.145 | 0.8883 | 0.6462 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 12000.145 | 0.3060 | -0.7144 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 12000.145 | 0.0793 | -0.9690 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 100 | uM | 12000.145 | 0.0157 | -0.9978 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000256 | uM | 12084.145 | 0.8688 | 0.7734 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00128 | uM | 12084.145 | 0.9931 | 0.9881 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0064 | uM | 12084.145 | 0.9943 | 0.9903 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.032 | uM | 12084.145 | 1.0612 | 1.1042 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 12084.145 | 1.0542 | 1.0924 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 12084.145 | 0.7811 | 0.6192 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 12084.145 | 0.2280 | -0.4352 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 12084.145 | 0.0019 | -0.9906 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Bosutinib | Src | nRTK | 100 | uM | 12084.145 | 0.0041 | -0.9818 | 1.1692 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 10693.145 | 0.9824 | 0.9586 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 10693.145 | 0.9513 | 0.8859 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 10693.145 | 0.9619 | 0.9106 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 10693.145 | 0.9951 | 0.9884 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 10693.145 | 0.9600 | 0.9061 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 10693.145 | 0.8450 | 0.6401 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 10693.145 | 0.7268 | 0.3736 | 0.8492 |